tradingkey.logo

tradingkey.logo
怜玢


Beta Bionics Inc

BBNX
りォッチリストに远加
21.710USD
-0.480-2.16%
終倀 09-23 16:00ET
976.73M時䟡総額
損倱額盎近12ヶ月PER

Beta Bionics Incに぀いお 䌁業名

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Beta Bionics Inc プロフィヌル


䌁業コヌドBBNX
䌚瀟名Beta Bionics Inc
䞊堎日Jan 30, 2025
最高経営責任者「CEO」Saint (Sean)
埓業員数291
蚌刞皮類Ordinary Share
決算期末Jan 30
本瀟所圚地11 Hughes
郜垂IRVINE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号92618
電話番号19494277785
りェブサむトhttps://www.betabionics.com
䌁業コヌドBBNX
䞊堎日Jan 30, 2025
最高経営責任者「CEO」Saint (Sean)

Beta Bionics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%

よくある質問

Beta Bionics Incの䞊䜍5名の株䞻は誰ですか


Beta Bionics Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Steven Russell, M.D., Ph.D.

Beta Bionics IncBBNXの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Beta Bionics Incの株匏を保有しおいる機関は264瀟あり、保有株匏の総垂堎䟡倀は玄49.25Mで、党䜓の110.51%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-2186348.00増加しおいたす。

Beta Bionics Incの最倧の収益源は䜕ですか


2026Q1においお、DME channel - iLet郚門がBeta Bionics Incにずっお最倧の収益を生み出しおおり、その金額は12.65Mで、党収益の39.52%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。